Výsledky vyhledávání - Ian Ford

Upřesnit hledání
  1. 1
    Pragmatic Trials

    Pragmatic Trials Autor Ian Ford, John Norrie

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Total Ischaemic Burden European Trial (TIBET): Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina

    Total Ischaemic Burden European Trial (TIBET): Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angi... Autor Henry J. Dargie, Ian Ford, Kim Fox

    Vydáno 1996
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Effect of Apomorphine on the Relationship between Local Cerebral Glucose Utilization and Local Cerebral Blood Flow (with an Appendix on its Statistical Analysis)

    Effect of Apomorphine on the Relationship between Local Cerebral Glucose Utilization and Local Cerebral Blood Flow (with an Appendix on its Statistical Analysis) Autor James McCulloch, Paul A. Kelly, Ian Ford

    Vydáno 1982
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Mortality in heart failure: clinical variables of prognostic value.

    Mortality in heart failure: clinical variables of prognostic value. Autor John G.F. Cleland, Henry J. Dargie, Ian Ford

    Vydáno 1987
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Are Routinely Collected NHS Administrative Records Suitable for Endpoint Identification in Clinical Trials? Evidence from the West of Scotland Coronary Prevention Study

    Are Routinely Collected NHS Administrative Records Suitable for Endpoint Identification in Clinical Trials? Evidence from the West of Scotland Coronary Prevention Study Autor Sarah Barry, Eleanor Dinnett, Sharon Kean, Allan Gaw, Ian Ford

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy

    Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy Autor Ian Ford, Heather Murray, Colin McCowan, Chris J. Packard

    Vydáno 2016
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    The Total Ischaemic Burden European Trial (TIBET): Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina

    The Total Ischaemic Burden European Trial (TIBET): Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with... Autor Kim Fox, Hugh Mulcahy, I. Findlay, Ian Ford, Henry J. Dargie

    Vydáno 1996
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I<sub>f</sub> Inhibitor Ivabradine Trial (SHIFT)

    Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I<sub>f</... Autor Karl Swedberg, Michel Komajda, Michael Böhm, Jeffrey Borer, Ian Ford, Luigi Tavazzi

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina

    Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina Autor Jean‐Claude Tardif, Ian Ford, Michał Tendera, Martial G. Bourassa, Kim Fox

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort

    High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort Autor Alan T. Clarke, P. Johnson, Gillian C. Hall, Ian Ford, Peter R. Mills

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial

    Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina... Autor Kim Fox, Ian Ford, Philippe Gabríel Steg, Michał Tendera, Michele Robertson, Roberto Ferrari

    Vydáno 2009
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?

    Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose? Autor Karl Swedberg, Michel Komajda, Michael Böhm, Jeffrey Borer, Michele Robertson, Luigi Tavazzi, Ian Ford

    Vydáno 2012
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial

    Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial Autor Michel Komajda, Luigi Tavazzi, Bernard Francq, Michael Böhm, Jeffrey Borer, Ian Ford, Karl Swedberg

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study

    Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study Autor Luigi Tavazzi, Karl Swedberg, Michel Komajda, Michael Böhm, Jeffrey Borer, Mitja Lainščak, Ian Ford

    Vydáno 2013
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model

    Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model Autor Ian Ford, Michele Robertson, Michel Komajda, Michael Böhm, Jeffrey Borer, Luigi Tavazzi, Karl Swedberg

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure

    Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure Autor Kim Fox, Ian Ford, Philippe Gabríel Steg, Jean‐Claude Tardif, Michał Tendera, Roberto Ferrari

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study

    Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study Autor Kim Fox, Ian Ford, Philippe Gabríel Steg, Jean‐Claude Tardif, Michał Tendera, Roberto Ferrari

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of <scp>SHIFT</scp>

    Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of <scp>SHIFT</scp> Autor Michel Komajda, Luigi Tavazzi, Karl Swedberg, Michael Böhm, Jeffrey Borer, Aurélie Moyne, Ian Ford

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta‐analysis

    Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta‐analysis Autor Michel Komajda, Michael Böhm, Jeffrey Borer, Ian Ford, Luigi Tavazzi, Matthieu Pannaux, Karl Swedberg

    Vydáno 2018
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population

    Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population Autor Edimar Alcides Bocchi, Michael Böhm, Jeffrey Borer, Ian Ford, Michel Komajda, Karl Swedberg, Luigi Tavazzi

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: